Axon Enterprise, Inc (NASDAQ:AXON) Receives $762.93 Consensus Target Price from Brokerages

Axon Enterprise, Inc (NASDAQ:AXON) has been given a consensus recommendation of “Moderate Buy” by the nineteen research firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $762.9333.

Several research analysts have recently issued reports on the stock. Royal Bank Of Canada dropped their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target for the company in a research report on Tuesday, January 6th. Piper Sandler decreased their price objective on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Barclays lowered their price objective on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd.

Axon Enterprise Price Performance

AXON opened at $574.01 on Friday. The stock has a 50-day moving average price of $536.08 and a 200-day moving average price of $617.87. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The firm has a market cap of $46.15 billion, a PE ratio of 377.64, a P/E/G ratio of 12.25 and a beta of 1.46. Axon Enterprise has a 1 year low of $396.41 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. Axon Enterprise’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.08 EPS. Sell-side analysts predict that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Activity

In other Axon Enterprise news, CAO Jennifer H. Mak sold 1,500 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the transaction, the chief accounting officer owned 12,240 shares of the company’s stock, valued at approximately $7,019,028. The trade was a 10.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $551.92, for a total transaction of $5,519,200.00. Following the transaction, the chief executive officer owned 3,110,997 shares in the company, valued at $1,717,021,464.24. This represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 56,634 shares of company stock valued at $31,534,295. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of large investors have recently made changes to their positions in the stock. NEOS Investment Management LLC lifted its position in shares of Axon Enterprise by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after buying an additional 11,482 shares in the last quarter. Vanguard Group Inc. increased its holdings in Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Axon Enterprise by 3.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock worth $132,349,000 after acquiring an additional 5,953 shares during the period. BIT Capital GmbH raised its stake in Axon Enterprise by 75.6% during the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock worth $2,537,000 after acquiring an additional 1,522 shares during the period. Finally, Wealthedge Investment Advisors LLC lifted its holdings in Axon Enterprise by 180.7% during the second quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock valued at $997,000 after purchasing an additional 775 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 revenue and bookings beat expectations — Axon reported quarterly revenue of ~$796.7M (up ~38.5% YoY) and said bookings were at record levels, driven by recurring software/services and AI products; investors are rewarding the growth narrative. Read More.
• Positive Sentiment: AI and acquisitions broaden the TAM — Axon is rolling out AI tools (Draft One) and expanding into emergency communications via buys like Carbyne and Prepared, pushing the company from hardware into a higher‑margin, recurring‑revenue public‑safety platform. Read More.
• Positive Sentiment: Hardware momentum in Connected Devices — demand for TASER 10, Axon Body 4 and counter‑drone solutions boosted device sales, helping current revenue strength and cross‑sell into Axon Cloud subscriptions. Read More.
• Neutral Sentiment: Street attention and bull narratives — multiple outlets and bullish newsletters have flagged Axon as a pick, increasing retail/institutional focus but also raising expectations. Read More.
• Negative Sentiment: Profitability collapsed despite revenue growth — quarterly net income plunged (reported near break‑even), compressing EPS and margins; that raises near‑term profitability and margin recovery questions. Read More.
• Negative Sentiment: Insider selling — Axon’s CAO sold 1,500 shares (~$860k), which may be viewed negatively by some investors even though the remaining insider stake remains material. Read More.
• Negative Sentiment: Analysts trimmed targets — some firms cut price targets (Morgan Stanley, Barclays) even as many maintain buy/overweight positions, signaling debate about valuation vs. execution. Read More.
• Negative Sentiment: High valuation and execution risk — AXON trades at a very high P/E, leaving the stock sensitive to execution on margin recovery, successful AI monetization and integration of acquisitions. Read More.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.